Frontlight ResearchEarly access
Active, not recruitingPhase 1/2
Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA
Key facts
- Who runs it
- University of Manchester
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1/2
- People taking part
- 5 people, planned
- Started
- 7 Jan 2020
- Ended
- 30 Oct 2026
- Type of study
- Interventional
- Treatments tested
- Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene
- Record updated
- 30 March 2025
Who can take part
- Age
- 3 months to 24 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Written informed consent of a legally authorized guardian(s)
- Age at baseline ≥3 months and ≤24 months
- Normal cognitive function or mild cognitive deterioration (subject has a Development Quotient (DQ) score ≥80) at baseline as determined by the Bayley Scale of Infant Development-third edition (BSID-III), cognitive domain)
- Sibling or relative of known MPS IIIA patients with rapidly progressing phenotype, or genotype associated with rapidly progressing phenotype, or presence of somatic features predictive of rapid progression
- SGSH activity ≤10% of the Lower Limit of Normal as measured in leukocytes, plus either (1) a normal enzyme activity level of at least one other sulfatase (to rule out multiple sulfatase deficiency) as measured in leukocytes or (2) two documented mutations in the SGSH gene
- Medically stable and able to accommodate the protocol requirements, including travel without placing an undue burden on the patient/patient's family, as determined by the CI
Who cannot take part
- The subject has received stem cell, gene therapy or enzyme replacement therapy (any route of administration)
- The subject is currently receiving psychotropic or other medications which, in the CI's opinion, would be likely to substantially confound test results
- The subject has received any investigational medicinal product (including Genistein) within 30 days prior to the Baseline visit or is scheduled to receive any investigational medicinal product during the course of the study
- Malignant neoplasia (except local skin cancer) or a documented history of hereditary cancer syndrome. Subjects with a prior successfully treated malignancy and a sufficient follow-up to exclude recurrence (based on oncologist opinion) can be included after discussion and approval by the Medical Monitor
- The receipt of live vaccinations within 30 days prior to study start
- The subject has a history of poorly controlled seizures
- Documented Human Immunodeficiency Virus (HIV) infection (positive HIV RNA and/or anti-p24 antibodies)
- Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome and acute myeloid leukaemia, or other serious haematological disorders
- The subject has a medical condition or extenuating circumstance that, in the opinion of the CI, might compromise the subject's ability to comply with protocol requirements, the subject's well-being or safety, or the interpretability of the subject's clinical data
- Visual or hearing impairment sufficient to preclude cooperation with neurodevelopmental testing
- Subject currently enrolled in other interventional clinical trials
- Contraindications for MRI scans
- Homozygous or compound heterozygous for the S298P mutation or any other mutation known to be associated to slow-progressing phenotype
- Severe behavioural disturbances due to reasons other than MPS IIIA and likely to interfere with protocol compliance, as determined by the CI
- Known sensitivity to busulfan
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients with MPS IIIA have a clinical disorder marked by severe and progressive brain disease and neurological symptoms due to the accumulation of undigested glycosaminoglycans in all cells of the body.
Read full original descriptionShow less
This study will be the first in human clinical trial to explore the safety, tolerability and clinical efficacy of ex vivo gene therapy (autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene) in MPSIIIA patients. Following treatment with the gene therapy patients will be followed up for a minimum of 3 years.
The group in the trial
- Haematopoietic stem cell gene therapy for MPS IIIATreatment being tested
Open label
Treatment: Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I-II, Study of Autologous CD34+ Haematopoietic Stem Cells Transduced Ex Vivo with CD11b Lentiviral Vector Encoding for Human SGSH in Patients with Mucopolysaccharidosis Type IIIA (MPS IIIa, Sanfilippo Syndrome Type A)
- Record updated
- 30 March 2025